CD33 (SIGLEC3) polyclonal (N-term), anti-human
€0.00
In stock
SKU
AC-AP1622A
Catalog Number: AC-AP1622A
Size: 80 µl, 400 µl
Isotype: Rabbit IgG
Clone Name: RB02425
Applications: IHC-P, WB
Datasheet
Request Information
Size: 80 µl, 400 µl
Isotype: Rabbit IgG
Clone Name: RB02425
Applications: IHC-P, WB
Datasheet
Request Information
Background:
SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2,6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.
Other Names:
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3
Target/Specificity:
This CD33 (SIGLEC3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-39 amino acids from the N-terminal region of human CD33 (SIGLEC3).
Antigen Region:
12-39
Antigen Type: Synthetic Peptide
Gene Name: CD33
Gene ID: 945
Primary Accession: P20138
NCBI Accession: NP_001076087.1;NP_001171079.1;NP_001763.3
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2,6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.
Other Names:
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3
Target/Specificity:
This CD33 (SIGLEC3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-39 amino acids from the N-terminal region of human CD33 (SIGLEC3).
Antigen Region:
12-39
Antigen Type: Synthetic Peptide
Gene Name: CD33
Gene ID: 945
Primary Accession: P20138
NCBI Accession: NP_001076087.1;NP_001171079.1;NP_001763.3
Format: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
| Is Featured? | No |
|---|
Write Your Own Review